Wedbush Securities increased its price target for Rezolute from $6 to $10, maintaining an 'Outperform' rating. This upgrade is driven by positive Phase 3 study results for tumor hyperinsulinism and a recent $100 million equity offering, signaling increased confidence in the company's prospects.
Wedbush Securities raised its price target for Rezolute (RZLT) from $6 to $10 and reiterated its 'Outperform' rating. This positive adjustment stems from two key developments: successful Phase 3 upLIFT study results for tumor hyperinsulinism, indicating potential for a new therapeutic, and a $100 million equity offering, which strengthens the company's financial position. This news is a significant positive for Rezolute, as it reflects analyst confidence in the company's clinical pipeline and financial stability. Short-term, this could lead to increased investor interest and upward pressure on RZLT's stock price. Long-term, successful commercialization of the drug for tumor hyperinsulinism would be a major growth driver. The key opportunity for traders is potential upside as the market digests the positive clinical data and analyst upgrade.